U.S. Markets closed

Analyzing Alexion Pharmaceuticals’ Top-Line Trends

Kenneth Smith
Analyzing Alexion Pharmaceuticals’ Top-Line Trends

Alexion Pharmaceuticals’ (ALXN) revenues increased $132.3 million to $1.04 billion in the second quarter of 2018 compared to the second quarter of 2017. For fiscal 2018 and fiscal 2019, Alexion Pharmaceuticals is expected to generate revenues of $4.04 billion and $4.72 billion, respectively, compared to $3.55 billion in fiscal 2017. Fiscal 2018 gross margins for its peers Abbott Laboratories (ABT), Amgen (AMGN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 59.10%, 85.94%, 70.09%, 69.64%, and 79.21%, respectively.